Anti-TPD52L3 Rabbit Polyclonal Antibody for WB, IF-P, ELISA - Q96J77

Core Product Specifications and Parameters

Biological Background: TPD52L3 Function and Localization

• TPD52L3, also known as tumor protein D55 (hD55) and testis development protein NYD-SP25, is a member of the TPD52-like protein family.
• The protein is specifically expressed in the testis, with expression levels 5.6-fold higher in adult testis compared to fetal testis, indicating a potential role in testicular development or maturation.
• Sequence analysis reveals a coiled-coil domain, suggesting the ability to engage in protein-protein interactions.
• The TPD52L3 gene undergoes alternative splicing, giving rise to multiple isoforms whose individual functions remain poorly characterized.
• The canonical isoform has a predicted molecular weight of 15.5 kDa (UniProt Q96J77), while the observed band in SDS-PAGE may migrate at approximately 16 kDa.
• Due to its restricted expression pattern, TPD52L3 may be involved in spermatogenesis or related reproductive processes.

Experimental Guidance and Technical Tips

• For Western blot, endogenous TPD52L3 may be detected around 16 kDa in human testis tissue lysates. Consider using a low molecular weight protein marker and optimizing transfer conditions.
• For immunofluorescence or immunoprecipitation, validate the antibody in a relevant cell line or primary testis cells. Pre-blocking with the immunogen peptide can serve as a specificity control.
• The antibody cross-reacts with mouse and rat samples, allowing for translational studies in rodent models. Verify its performance in your species-specific system.
• Due to the low molecular weight and potential coiled-coil domain, ensure denaturing conditions are maintained throughout sample preparation for optimal epitope exposure.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio offers diagnostic manufacturers, laboratories, and research institutes seamless access to validated IVD raw materials, including this anti-TPD52L3 antibody for testis biology and cancer research. Our portfolio encompasses optimized monoclonal/polyclonal antibodies, recombinant proteins, and bulk ancillary reagents, simplifying your procurement from discovery to clinical development. For rare or custom targets, our technical team assists in sourcing and feasibility assessment, ensuring you obtain the critical materials needed to accelerate your projects.